B-cell acute lymphoblastic leukemia and Burkitt lymphoma

doi:10.1017/CBO9780511471001.019

18 - B-cell acute lymphoblastic leukemia and Burkitt lymphoma

from Part III - Evaluation and treatment

Published online by Cambridge University Press: 01 July 2010

John T. Sandlund and

Ian T. Magrath

Edited by

Ching-Hon Pui

Show author details

John T. Sandlund: Affiliation:
Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
Ian T. Magrath: Affiliation:
Professor of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD
Ching-Hon Pui: Affiliation:
St. Jude Children's Research Hospital, Memphis

Book contents

Get access

Summary

Introduction

B-cell acute lymphoblastic leukemia (B-cell ALL) has historically accounted for approximately 2% of childhood ALLs diagnosed in the United States each year. This malignancy has clinical, histologic, immunophenotypic, and cytogenetic features similar to those of Burkitt lymphoma, a high-grade B-cell non-Hodgkin lymphoma (NHL). Hence, B-cell ALL and Burkitt lymphoma are usually considered to represent a spectrum of the same disease process. In children, the distinction between Burkitt lymphoma with bone marrow involvement and B-cell ALL is arbitrarily based on the degree of marrow infiltration. Patients who have less than 25% replacement of normal marrow with lymphoblasts are considered to have advanced (stage IV) Burkitt lymphoma, whereas those with more extensive marrow replacement are given the diagnosis of B-cell ALL. These two groups are treated with the same protocols used for patients with advanced-stage Burkitt lymphoma that has not disseminated to the marrow (stage III). Although limited-stage Burkitt lymphoma is also thought to be included in this disease spectrum, it is less common in children than are the advanced forms and is treated with much less intensive therapy. Hence, in describing treatment, we will focus on stages III and IV Burkitt lymphoma and B-cell ALL.

Advances in our understanding of the molecular pathogenesis of these malignancies and improvements in treatment outcome have been striking over the past 20 years. Currently, a 75% to 85% event-free survival rate can be expected for children with B-cell ALL. By contrast, less than 50% of these patients were event-free survivors 20 years ago.

Information

Type: Chapter
Information: Childhood Leukemias , pp. 487 - 498

DOI: https://doi.org/10.1017/CBO9780511471001.019 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Pui, C.-H.Childhood leukemias. N Engl J Med, 1995; 332: 1618– 30.CrossRef Google Scholar PubMed

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma: summary and description of a working formulation for clinical usage. Cancer, 1982; 49: 2112–35.3.0.CO;2-2>CrossRef

Harris, N. L., Jaffe, E. S., Stein, H., et al.A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994; 84: 1361–92.Google Scholar PubMed

Sandlund, J. T., Downing, J. R., & Crist, W. M.Non-Hodgkin's lymphoma in childhood. N Engl J Med, 1996; 334: 1238–48.CrossRef Google Scholar PubMed

Magrath, I. T. Malignant non-Hodgkin's lymphomas in children. In , P. A. Pizzo & , D. G. Poplack, eds., Principles and Practice of Pediatric Oncology, 4th edn. (Philadelphia, PA: Lippincott, 2002), pp. 661–706.Google Scholar

Murphy, S. B., Fairclough, D. L., Hutchison, R. E., et al.Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol, 1989; 7: 186–93.CrossRef Google Scholar

Jaffe, E. S., Harris, N. L., Stein, H., & Vardiman, J. W., eds., World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (Lyon, France:IARC Press, 2001).Google Scholar

Hutchison, R. E., Finch, C., Kepner, J., et al.Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons. Ann Oncol, 2000; 11(Suppl. 1): 35–8.CrossRef Google Scholar PubMed

Hutchison, R. E., Murphy, S. B., Fairclough, D. L., et al.Diffuse small noncleaved-cell lymphoma in children, Burkitt's versus non-Burkitt's types: results from the Pediatric Oncology Group and St. Jude Children's Research Hospital. Cancer, 1989; 64: 23–8.3.0.CO;2-T>CrossRef Google Scholar PubMed

Behm, F. G. & Campana, D. Immunophenotyping. In , C.-H. Pui, ed., Childhood Leukemias (New York: Cambridge University Press, 1999), pp. 111–44.Google Scholar

Navid, F., Mosijczuk, A. D., Head, D. R., et al.Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience. Leukemia, 1999; 13: 135–41.CrossRef Google Scholar PubMed

Loh, M. L., Samson, Y., Motte, E., et al.Translocation (2;8) (p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/ AML1 gene rearrangement in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet, 2000; 122: 79–82.CrossRef Google Scholar

Magrath, I. T. & Bhatia, K. Pathogenesis of small noncleaved cell lymphomas (Burkitt's lymphoma). In , I. T. Magrath, ed., The Non-Hodgkin Lymphomas (London: Arnold, 1997).Google Scholar

Dalla-Favera, R., Bregni, M., Erikson, J., et al.Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A, 1982; 79: 7824–7.CrossRef Google Scholar PubMed

Taub, R., Kirsch, I., Morton, C., et al.Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A, 1982; 79: 7837–41.CrossRef Google Scholar PubMed

Kelly, K. & Siebenlist, U.Mitogenic activation of normal T-cells leads to increased initiation of transcription in the c-myc locus. J Biol Chem, 1988; 263: 4828–31.Google Scholar PubMed

Kelly, K. & Sienbenlist, U.The regulation and expression of c-myc in normal and malignant cells. Annu Rev Immunol, 1986; 4: 317–38.CrossRef Google Scholar PubMed

Luscher, B. & Eisenman, R. N.New light on Myc and Myb. Part I. Myc. Genes Dev, 1990; 4: 2025–35.CrossRef Google Scholar PubMed

Packham, G. & Cleveland, J. L.Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol, 1994; 14: 5741–7.CrossRef Google Scholar PubMed

Blackwood, E. M. & Eisenman, R. N.Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science, 1991; 251: 1211–17.CrossRef Google Scholar PubMed

Prendergast, G. C., Lawe, D., & Ziff, E. B.Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras co-transformation. Cell, 1991; 65: 395–407.CrossRef Google Scholar

Ayer, D. E., Kretzner, L., & Eisenman, R. N.Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell, 1993; 72: 211–22.CrossRef Google Scholar PubMed

Zervos, A. S., Gyuris, J., & Brent, R.Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites [Erratum published in Cell, 1994; 79: 388]. Cell, 1993; 72: 223–32.Google Scholar

Amati, B. & Land, H.Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev, 1994; 4: 102–8.CrossRef Google Scholar PubMed

Ayer, D. E., Lawrence, Q. A., & Eisenman, R. N.Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell, 1995; 80: 767–76.CrossRef Google Scholar PubMed

Gu, S., Cechova, K., Tassi, V., et al.Opposite regulation of gene transcription and cell proliferation by c-Myc and max. Proc Natl Acad Sci U S A, 1993; 90: 2935–9.CrossRef Google Scholar PubMed

Croce, C. M., Erikson, J., Ar-Rushdi, A., et al.Translocated c-myc oncogene of Burkitt lymphoma is transcribed in plasma cells and repressed in lymphoblastoid cells. Proc Natl Acad Sci U S A, 1984; 81: 3170–4.CrossRef Google Scholar PubMed

Gu, W., Bhatia, K., Magrath, I. T., et al.Binding and suppression of the Myc transcriptional activation domain by p107. Science, 1994; 264: 251–4.CrossRef Google Scholar PubMed

Sandlund, J. T., Neckers, L. M., Schneller, H. E., et al.Theophylline-induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhanced sequences. Cancer Res, 1993; 53: 127–32.Google Scholar

Zajac-Kaye, M., Yu, B., & Ben-Baruch, N.Downstream regulatory elements in the c-myc gene. Curr Top Microbiol Immunol, 1990; 166: 279–84.Google Scholar PubMed

Adams, J. M., Harris, A. W., Pinkert, C. A., et al.The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature, 1985; 318: 533–8.CrossRef Google Scholar PubMed

Cory, S. & Adams, J. M.Transgenic mice and oncogenesis. Annu Rev Immunol, 1988; 6: 25–48.CrossRef Google Scholar PubMed

Packham, G. & Cleveland, J. L.c-Myc and apoptosis. Biochim Biophys Acta, 1995; 1242: 11–28.Google Scholar PubMed

Henderson, S., Rowe, M., Gregory, C., et al.Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 1991; 65: 1107–15.CrossRef Google Scholar PubMed

Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J. & Cleveland, J. L.Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev, 1999; 13: 2658–69.CrossRef Google Scholar PubMed

Eischen, C. M., Roussel, M. F., Korsmeyer, S. J. & Cleveland, J. L.Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol, 2001; 21: 7653–62.CrossRef Google Scholar PubMed

Eischen, C. M., Woo, D., Roussel, M. F. & Cleveland, J. L.Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol, 2001; 21: 5063–70.CrossRef Google Scholar PubMed

Gaidano, G., Ballerini, P., Gong, J. Z., et al.p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A, 1991; 88: 5413–17.CrossRef Google Scholar PubMed

Bhatia, K. G., Gutiérrez, M. I., Huppi, K., et al.The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res, 1992; 53: 4273–6.Google Scholar

Rockwood, L. D., Torrey, T. A., Kim, J. S., et al.Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene, 2002; 21: 7235–40.CrossRef Google Scholar

Robison, L. L. General principles of the epidemiology of childhood cancer. In , P. A. Pizzo & , D. G. Poplack, eds., Principles and Practice of Pediatric Oncology, 2nd edn. (Philadelphia, PA: Lippincott, 1993), pp. 3–10.Google Scholar

Bleyer, W. A.The impact of childhood cancer on the United States and the world. CA Cancer J Clin, 1990; 40: 355–66.CrossRef Google Scholar

Parker, S. L., Tong, T., Bolden, S. & Wingo, P. A.Cancer Statistics, 1996. CA Cancer J Clin, 1996; 46: 3–4.CrossRef Google Scholar PubMed

Percy, C. L., Smith, M. A, Linet, M., et al. Lymphomas and reticuloendothelial neoplasms. In , L. A. G. Ries, , M. A. Smith, , J. G. Gurney, et al., eds., Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995, NIH Publication 99–4649 (Bethesda, MA: National Cancer Institute, SEER Program, 1999), pp. 35–49.Google Scholar

Young, J. L. Jr., Ries, L. G., Silverberg, E., Horm, J. W., & Miller, R. W.Cancer incidence, survival and mortality for children younger than age 15 years. Cancer, 1986; 58: 598–602.3.0.CO;2-C>CrossRef Google Scholar PubMed

Taylor, A. M. R., Metcalfe, J. A., Thick, J., et al.Leukemia and lymphoma in ataxia telangiectasia. Blood, 1996; 87: 423–38.Google Scholar PubMed

Gatti, R. A. & Good, R. A.Occurrence of malignancy in immunodeficiency disease. A literature review. Cancer, 1971; 28: 89–98.3.0.CO;2-Q>CrossRef Google Scholar PubMed

Filipovich, A. H., Heinitz, K. J., Robison, L. L., & Frizzera, G.The immunodeficiency cancer registry. A research resource. Am J Pediat Hematol Oncol, 1987; 9: 183–4.CrossRef Google Scholar PubMed

Ellaurie, M., Wiznia, A., Bernstein, L., et al.Lymphoma in pediatric HIV infection. Pediatr Res, 1989; 25: 150A.Google Scholar

Parekh, S., Ratech, H., & Sparano, J. A.Human immunodeficiency virus-associated lymphoma. Clin Adv Hematol Oncol, 2003; 1: 295–301.Google Scholar PubMed

Levine, A. M., Seneviratne, L., Espina, B. M., et al.Evolving characteristics of AIDS-related lymphoma. Blood, 2000; 96: 4084–90.Google Scholar PubMed

Murphy, S. B., Jenson, H. B., McClain, K. L., et al.AIDS related tumors. Med Pediatr Oncol, 1997; 29: 381.Google Scholar

McClain, K. L., Joshi, V. V., & Murphy, S. B.Cancers in children with HIV infection. Hematol Oncol Clin North Am, 1996; 10: 1189–201.CrossRef Google Scholar PubMed

Pluda, J. M., Yarchoan, R., Jaffe, E. S., et al.Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med, 1990; 113: 276.CrossRef Google Scholar

Sandlund, J., Fonseca, T., Leimig, T., et al.Predominance and characteristics of Burkitt lymphoma among children with non-Hodgkin lymphoma in northeastern Brazil. Leukemia, 1997; 11: 743–6.CrossRef Google Scholar PubMed

Gutierrez, M. I., Bhatia, K., Barriga, F., et al.Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood, 1992; 79: 3261–6.Google Scholar PubMed

Kuhn-Hallek, I., Sage, D. R., Stein, L., et al.Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B-cells. Blood, 1995; 85: 1289–99.Google Scholar PubMed

Wilson, J. B. & Levine, A. J.The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr Top Microbiol Immunol, 1992; 182: 375–85.Google Scholar PubMed

Bhatia, K., Raj, A., Gutierrez, M. I., et al.Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphoma. Oncogene, 1996; 13: 177–81.Google Scholar

Ruf, I. K., Rhyne, P. W., Yang, H., et al.Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in burkitt lymphoma. Mol Cell Biol, 1999; 19: 1651–60.CrossRef Google Scholar PubMed

Razzouk, B. I., Srinivas, S., Sample, C. E., et al.Epstein–Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis, 1996; 173: 529–35.CrossRef Google Scholar PubMed

Sandlund, J. T., Murphy, S. B., Santana, V. M., et al.Central nervous system involvement in children with newly diagnosed non-Hodgkin lymphoma. J Clin Oncol, 2000; 18: 3018–24.CrossRef Google Scholar

Carr, R., Barrington, S. F., Madan, B., et al.Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood, 1998; 91: 3340–6.Google Scholar PubMed

Murphy, S. B.Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol, 1980; 7: 332–9.Google Scholar PubMed

Pui, C.-H., Relling, M. V., Lascombes, F., et al.Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia, 1997; 11: 1813–16.CrossRef Google Scholar PubMed

Pui, C.-H., Mahmoud, H. H., Wiley, J. M., et al.Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol, 2001; 19: 697–704.CrossRef Google Scholar PubMed

Murphy, S. B., Bowman, W. P., Abromowitch, M., et al.Results of treatment of advanced-stage Burkitt's lymphoma and B cell (sIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol, 1986; 4: 1932–9.CrossRef Google Scholar

Bowman, W. P., Shuster, J., Cook, B., et al.Improved survival for children with B cell acute lymphoblastic leukemia and stage IV small noncleaved cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol, 1996; 14: 1252–61.CrossRef Google Scholar PubMed

Patte, C., Philip, T., Rodary, C., et al.High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol, 1991; 9: 123–32.CrossRef Google Scholar PubMed

Patte, C., Leverger, G., Perel, Y., et al.Updated results of the LMB 86 protocol of the French Pediatric Oncology Society (SFOP) for B-cell non-Hodgkin's lymphomas (B-NHL) with CNS involvement (CNS+) and B-ALL [abstract]. Med Pediatr Oncol, 1990; 18: 397.Google Scholar

Reiter, A., Schrappe, M., Ludwig, W. D., et al.Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood, 1992; 80: 2471–8.Google Scholar PubMed

Sposto, R., Meadows, A. T., Chilcote, R. R., et al.Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children's Cancer Group. Med Pediatr Oncol, 2001; 37: 432–41.CrossRef Google Scholar PubMed

Cairo, M. S., Sposto, R., Perkins, S. L., et al.Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol, 2003; 120: 660–70CrossRef Google Scholar PubMed

Magrath, I. T., Janus, C., Edwards, B. K., et al.An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood, 1984; 63: 1102–11.Google Scholar PubMed

Schwenn, M. R., Blattner, S. R., Lynch, E., et al.HiC-COM: a 2-month intensive lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol, 1991; 9: 133–8.CrossRef Google Scholar PubMed

Patte, C., Philip, T., Rodary, C., et al.Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol, 1986; 4: 1219–26.CrossRef Google Scholar PubMed

Magrath, I., Adde, M., Shad, A., et al.Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol, 1996; 14: 925–34.CrossRef Google Scholar PubMed

Reiter, A., Schrappe, M., Parwaresch, R., et al.Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage – a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol, 1995; 13: 359–72.CrossRef Google Scholar

Woessmann, W., Seidemann, K., Mann, G., et al.The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood, 2005; 105: 948–58.CrossRef Google Scholar PubMed

Pillon, M., Di Tullio, M. T., Garaventa, A., et al.Long-term results of the first Italian Association of Pediatric Hematology and Oncology Protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer, 2004; 101: 385–94CrossRef Google Scholar

Anderson, J. R., Jenkis, R. D. T., Wilson, J. F., et al.Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Group. J Clin Oncol, 1993; 11: 1024–32.CrossRef Google Scholar PubMed

Adde, M., Shad, A., Venzon, D., et al.Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol, 1998; 25 (Suppl. 4): 33–9.Google Scholar PubMed

Soussain, C., Patte, C., Ostronoff, M., et al.Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood, 1995; 85: 664–74.Google Scholar PubMed

Patte, C., Auperin, A., Michon, J., et al.The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood, 2001; 97: 3370–9.CrossRef Google Scholar PubMed

Reiter, A., Schrappe, M., Tiemann, M., et al.Improved treatment results in childhood B-cell neoplasma with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood, 1999; 94: 3294–306.Google Scholar

Mead, G. M., Sydes, M. R., Walewski, J., et al.An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 Study. Eur Soc Med Oncol, 2002; 13: 1264–74.CrossRef Google Scholar PubMed

Kung, F. H., Harris, M. B., & Krischer, J. P.Isofamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study. Med Pediatr Oncol, 1999; 32: 225–6.3.0.CO;2-N>CrossRef Google Scholar

Philip, T., Biron, P., Philip, I., et al.Massive therapy and autologous bone marrow transplantation in pediatric and young adults with Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience). Eur J Cancer Clin Oncol, 1986; 22: 1015–27.CrossRef Google Scholar

Philip, T., Armitage, J. O., Spitzer, G., et al.High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med, 1987; 316: 1493–8.CrossRef Google Scholar PubMed

Philip, T., Hartmann, O., Biron, P., et al.High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol, 1988; 6: 1118–24.CrossRef Google Scholar PubMed

Bureo, E., Ortega, J. J., Muñoz, A., et al.Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Bone Marrow Transplant, 1995; 15: 353–9.Google Scholar PubMed

Ladenstein, R., Pearce, R., Hartmann, O., et al.High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood, 1997; 90: 2921–30.Google Scholar PubMed

Appelbaum, F., Deisseroth, A. B., Graw, R. G., et al.Prolonged complete remission following high-dose chemotherapy of Burkitt's lymphoma in relapse. Cancer, 1978; 41: 1059–63.3.0.CO;2-N>CrossRef Google Scholar PubMed

Sandlund, J. T., Bowman, L., Heslop, H. E., et al.Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy, 2002; 4: 253–8.CrossRef Google Scholar PubMed

Haddy, T. B., Adde, M. A., McCalla, J., et al.Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol, 1998; 16: 2070–9.CrossRef Google Scholar PubMed

Colombat, P., Salles, G., Brousse, N., et al.Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 2001; 97: 101–6.CrossRef Google Scholar PubMed

Coiffier, B., Haioun, C., Ketterer, N., et al.Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 1998; 92: 1927–32.Google Scholar PubMed

Veerman, A. J. P., Nuijens, J. H., Schoot, C. E., Kardos, G. & Zwaan, C. H. M.Rituximab in the treatment of childhood B-ALL and Burkitt's lymphoma, report on three cases [abstract]. Blood, 1999; 94(Suppl. 1): 269b.Google Scholar

McManaway, M. E., Neckers, L. M., Loke, S. L., et al.Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet, 1990; 335: 808–11.CrossRef Google Scholar PubMed

Magrath, I. T.Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomas. Ann Oncol, 1994; 5(Suppl. 1): S67–70.CrossRef Google Scholar PubMed

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.